(PTGX) Protagonist Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.526m USD | Total Return: 116.1% in 12m

Oral Peptides, Hormone Mimetics, Injectable Therapies
Total Rating 34
Safety 28
Buy Signal -0.34
Biotechnology
Industry Rotation: -8.2
Market Cap: 6.53B
Avg Turnover: 55.3M
Risk 3d forecast
Volatility46.9%
VaR 5th Pctl7.52%
VaR vs Median-2.63%
Reward TTM
Sharpe Ratio1.76
Rel. Str. IBD86.1
Rel. Str. Peer Group67.8
Character TTM
Beta-0.331
Beta Downside-1.473
Hurst Exponent0.319
Drawdowns 3y
Max DD52.15%
CAGR/Max DD1.15
CAGR/Mean DD4.18
EPS (Earnings per Share) EPS (Earnings per Share) of PTGX over the last years for every Quarter: "2021-03": -0.54, "2021-06": -0.69, "2021-09": -0.7, "2021-12": -0.77, "2022-03": -0.43, "2022-06": -0.84, "2022-09": -0.64, "2022-12": -0.69, "2023-03": -0.67, "2023-06": -0.68, "2023-09": -0.58, "2023-12": 0.44, "2024-03": 3.26, "2024-06": -0.5, "2024-09": -0.54, "2024-12": 1.98, "2025-03": -0.19, "2025-06": -0.55, "2025-09": -0.62, "2025-12": -0.69, "2026-03": 0.05,
Last SUE: 0.59
Qual. Beats: 0
Revenue Revenue of PTGX over the last years for every Quarter: 2021-03: 6.189, 2021-06: 2.265, 2021-09: 10.286, 2021-12: 8.617, 2022-03: 25.722, 2022-06: 0.859, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 60, 2024-03: 254.953, 2024-06: 4.167, 2024-09: 4.675, 2024-12: 170.638, 2025-03: 28.321, 2025-06: 5.546, 2025-09: 4.712, 2025-12: 7.437, 2026-03: 56.368,
Rev. CAGR: -12.43%
Rev. Trend: -10.8%
Last SUE: 0.68
Qual. Beats: 0

Warnings

High Debt while negative Cash Flow

Beneish M-Score 0.35 > -1.5 - likely earnings manipulation

Altman Z'' -9.68 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

Confidence

Description: PTGX Protagonist Therapeutics

Protagonist Therapeutics, Inc. (PTGX) is a biopharmaceutical company specializing in the discovery and development of peptide-based chemical entities. The company’s primary clinical focus is on oral and injectable treatments for chronic inflammatory diseases and rare blood disorders, utilizing a proprietary technology platform to create synthetic peptides that mimic or block natural biological pathways.

The current pipeline features two lead candidates: Rusfertide, an injectable hepcidin mimetic in Phase 3 trials for polycythemia vera, and Icotyde, an oral peptide targeting plaque psoriasis. Peptide therapeutics occupy a specific niche between small molecules and biologics, often offering high selectivity with lower toxicity profiles. This business model typically involves high capital expenditure during lengthy clinical trial phases, often leading to strategic partnerships with larger pharmaceutical firms for global commercialization.

The company is further diversifying into the metabolic space with candidates for obesity and atopic dermatitis. To better understand how these clinical milestones could impact long-term valuation, consider reviewing the detailed projections available on ValueRay. Protagonist Therapeutics remains headquartered in Newark, California, and has operated as a clinical-stage entity since its incorporation in 2006.

Headlines to Watch Out For
  • Rusfertide Phase 3 clinical trial results for polycythemia vera determine valuation
  • J&J collaboration milestones and royalties for oral peptide Icotyde drive revenue
  • Expansion of oral IL-17 antagonist pipeline into obesity and skin diseases
  • FDA regulatory approval timelines for first-in-class injectable hepcidin mimetic
  • Cash runway and R&D expenditure for early-stage metabolic disease candidates
Piotroski VR-10 (Strict) 0.0
Net Income: -114.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.17 > 0.02 and ΔFCF/TA -61.85 > 1.0
NWC/Revenue: 781.6% < 20% (prev 274.7%; Δ 507.0% < -1%)
CFO/TA -0.17 > 3% & CFO -116.6m > Net Income -114.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 17.76 > 1.5 & < 3
Outstanding Shares: last quarter (70.5m) vs 12m ago 11.96% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 10.29% > 50% (prev 28.00%; Δ -17.71% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -9.68
A: 0.83 (Total Current Assets 613.5m - Total Current Liabilities 34.5m) / Total Assets 697.5m
B: -0.67 (Retained Earnings -466.9m / Total Assets 697.5m)
C: -0.19 (EBIT TTM -135.4m / Avg Total Assets 719.8m)
D: -11.13 (Book Value of Equity -467.2m / Total Liabilities 42.0m)
Altman-Z'' = -9.68 = D
Beneish M 0.35
DSRI: 5.92 (Receivables 57.1m/27.1m, Revenue 74.1m/207.8m)
GMI: 1.01 (GM 98.35% / 99.28%)
AQI: 0.63 (AQ_t 0.10 / AQ_t-1 0.17)
SGI: 0.36 (Revenue 74.1m / 207.8m)
TATA: 0.00 (NI -114.7m - CFO -116.6m) / TA 697.5m)
Beneish M = 0.35 (Cap -4..+1) = D
What is the price of PTGX shares?

As of May 24, 2026, the stock is trading at USD 102.01 with a total of 385,743 shares traded.
Over the past week, the price has changed by -2.93%, over one month by -6.03%, over three months by +14.55% and over the past year by +116.05%.

Is PTGX a buy, sell or hold?

Protagonist Therapeutics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy PTGX.

  • StrongBuy: 5
  • Buy: 4
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the PTGX price?
Analysts Target Price 115.8 13.5%
Protagonist Therapeutics (PTGX) - Fundamental Data Overview as of 19 May 2026
P/E Forward = 23.753
P/S = 88.1185
P/B = 9.7487
Revenue TTM = 74.1m USD
EBIT TTM = -135.4m USD
EBITDA TTM = -133.9m USD
Long Term Debt = 7.44m USD (estimated: total debt 9.78m - short term 2.34m)
Short Term Debt = 2.34m USD (from shortTermDebt, last quarter)
Debt = 9.78m USD (from shortLongTermDebtTotal, last quarter) (leases 9.78m already included)
Net Debt = -538.0m USD (calculated: Debt 9.78m - CCE 547.8m)
Enterprise Value = 5.99b USD (6.53b + Debt 9.78m - CCE 547.8m)
 Interest Coverage Ratio = unknown (Ebit TTM -135.4m / Interest Expense TTM 0.0)
 EV/FCF = -51.49x (Enterprise Value 5.99b / FCF TTM -116.3m)
FCF Yield = -1.94% (FCF TTM -116.3m / Enterprise Value 5.99b)
 FCF Margin = -157.0% (FCF TTM -116.3m / Revenue TTM 74.1m)
 Net Margin = -154.9% (Net Income TTM -114.7m / Revenue TTM 74.1m)
 Gross Margin = unknown ((Revenue TTM 74.1m - Cost of Revenue TTM 1.23m) / Revenue TTM)
 Tobins Q-Ratio = 8.59 (Enterprise Value 5.99b / Total Assets 697.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.78m)
Taxrate = 21.0% (US default 21%)
NOPAT = -107.0m (EBIT -135.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.76 (Total Current Assets 613.5m / Total Current Liabilities 34.5m)
Debt / Equity = 0.01 (Debt 9.78m / totalStockholderEquity, last quarter 655.5m)
 Debt / EBITDA = 4.02 (negative EBITDA) (Net Debt -538.0m / EBITDA -133.9m)
 Debt / FCF = 4.63 (negative FCF - burning cash) (Net Debt -538.0m / FCF TTM -116.3m)
 Total Stockholder Equity = 645.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.94% (Net Income -114.7m / Total Assets 697.5m)
RoE = -10.31% (Net Income TTM -114.7m / Total Stockholder Equity 1.11b)
RoCE = -12.09% (EBIT -135.4m / Capital Employed (Equity 1.11b + L.T.Debt 7.44m))
 RoIC = -16.08% (negative operating profit) (NOPAT -107.0m / Invested Capital 665.2m)
 WACC = 4.81% (E(6.53b)/V(6.54b) * Re(4.82%) + D(9.78m)/V(6.54b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 4.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 46.67 | Cagr: 6.03%
 [DCF] Fair Price = unknown (Cash Flow -116.3m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.59 | # QB: 0
Revenue Correlation: -10.82 | Revenue CAGR: -12.43% | SUE: 0.68 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.72 | Chg30d=+21.31% | Revisions=-20% | Analysts=0
EPS next Quarter (2026-09-30): EPS=2.32 | Chg30d=+121.21% | Revisions=N/A | Analysts=9
EPS current Year (2026-12-31): EPS=4.06 | Chg30d=+46.40% | Revisions=+11% | GrowthEPS=+298.1% | GrowthRev=+983.1%
EPS next Year (2027-12-31): EPS=-0.89 | Chg30d=-105.20% | Revisions=+14% | GrowthEPS=-121.9% | GrowthRev=-71.6%
[Analyst] Revisions Ratio: -20%